ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1510

Depression Is a Major Driver of Functional Capacity in Patients with Rheumatoid Arthritis Regardless of Disease Activity

Carolina Ayelen Isnardi1, Dafne Capelusnik2, Emilce E Schneeberger3, Marcela Bazzarelli4, Laura Barloco5, Eliana Soledad Blanco6, Alejandro Benitez7, Federico Lujan Benavidez6, Santiago Scarafia8, María Alicia Lázaro8, Rodolfo Perez-Alamino9, Francisco Colombres10, María Paula Kohan11, Julia Sosa11, Luciana Gonzalez Lucero12, Ana Lucia Barbaglia12, Hernán Maldonado Ficco13 and Gustavo Citera14, 1Reumatology, Instituto de Rehabilitación Psicofísica, CABA, Argentina, 2Reumatology, Instituto de Rehabilitación Psicofísica, Argentina, CABA, Argentina, 3Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Reumatology, Hospital Interzonal General de Agudos Petrona V. de Cordero, Buenos Aires, Argentina, 5Terapia Ocupacional, Hospital Interzonal General de Agudos Petrona V. de Cordero, Buenos Aires, Argentina, 6Reumatology, Hospital General de Agudos Dr. Cosme Argerich, CABA, Argentina, 7Rheumatology, Hospital Cosme Argerich, Ciudad de Buenos Aires, Buenos Aires, Argentina, 8Reumatology, Instituto de Asistencia Reumatológica Integral, Buenos Aires, Argentina, 9Rheumatology Department, Hospital de Clínicas Pte. Dr. Nicolás Avellaneda, Tucumán, Argentina, 10Reumatology, Hospital de Clínicas Pte. Dr. Nicolás Avellaneda, Tucuman, Argentina, 11Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, CABA, Argentina, 12Hospital Angel C. Padilla, Tucuman, Argentina, 13Rheumatology Section, Hospital San Antonio de Padua, Río Cuarto- Córdoba, Argentina, 14Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Depression and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestions, and Outcomes Poster – ARHP

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Depression is one of the most frequent comorbidity in RA patients. It´s presence is associated with higher healthcare costs, mortality rate and reduced odds of achieving a good treatment response. The aim of our study was to determine the prevalence of depression in Argentinean patients with RA and to establish its relationship with different sociodemographic and clinical factors. 

Methods:

Consecutive patients ≥18 years old, with a diagnosis of RA according to ACR-EULAR 2010 criteria were included.  Sociodemographic data (sex, age, work and marital status, physical activity), comorbidities, RA characteristics (disease duration, RF and anti-CCP, presence of erosions), disease activity (joint count (28), composite indexes, pain, patient’s and physician´s global assessment -NVS-, morning stiffness), CRP, ESR and current treatment were registered. Questionnaires were administered to assess quality of life by EQ-5D-3L and QOL-RA, functional capacity by HAQ-A and depression by PHQ-9. Major depression was defined as a PHQ-9 score ≥10. PHQ-9 scores of 5-9, 10-14, 15-19, ≥20 represented mild, moderate, moderate/severe and severe depression, respectively. Patients with difficulties in answering the questionnaires (illiterate, blind) and with decompensated comorbidities were excluded. Statistical analysis: Student´s T, ANOVA and Chi2 tests. Multiple logistic regression.

Results:

258 patients were included. 85.7% were females, with a median (m) age of 54 years (IQR 45-62) and m disease duration of 9 years (IQR 3.6-16.7). Disease activity by DAS28-ESR was m 3.5 (IQR 2.5-4.5). The m PHQ-9 score was 6 (IQR 2-12.3). The prevalence of mayor depression was 33.7%. 66 (25.6%), 42 (16.3%), 27 (10.5%) and 18 (7%) patients presented mild, moderate, moderate/severe and severe depression, respectively. Patients with mayor depression had worst functional capacity (HAQ mean 1.56 ± 0.78 vs 0.69 ±0.65, p 0.0001), poorer quality of life (QOL-RA mean 5.38 ± 1.78 vs 7.31 ±1.61, p 0.0001), more pain (NVS mean 56.15 ± 27.48 mm vs 33.42 ± 25.72 mm, p 0.0001) and higher disease activity (DAS28-ERS mean 4.33 ±1.39 vs 3.3 ± 1.28, p 0.0001). Unemployment, presence of comorbidities, and less physical activity were more frequent in this group. No differences between early arthritis patients (≤ 2 years) and established rheumatoid arthritis (> 2 years) were seen. In the multivariate analysis, worst functional capacity and quality of life were independently associated to the presence of mayor depression. Patients with moderate and severe depression had worse functional capacity, independently of disease activity. (Fig.1)

Conclusion:

The prevalence of mayor depression measured by PHQ-9 score in this Argentinean cohort of rheumatoid arthritis patients was 33.7%. Patients with depression had a significant impact on functional capacity and quality of life regardless of disease activity.

 


Disclosure: C. A. Isnardi, None; D. Capelusnik, None; E. E. Schneeberger, None; M. Bazzarelli, None; L. Barloco, None; E. S. Blanco, None; A. Benitez, None; F. L. Benavidez, None; S. Scarafia, None; M. A. Lázaro, None; R. Perez-Alamino, None; F. Colombres, None; M. P. Kohan, None; J. Sosa, None; L. Gonzalez Lucero, None; A. L. Barbaglia, None; H. Maldonado Ficco, None; G. Citera, Bristol-Myers Squibb, Pfizer, AbbVie, Roche, Eli Lilly, Genzyme, 5.

To cite this abstract in AMA style:

Isnardi CA, Capelusnik D, Schneeberger EE, Bazzarelli M, Barloco L, Blanco ES, Benitez A, Benavidez FL, Scarafia S, Lázaro MA, Perez-Alamino R, Colombres F, Kohan MP, Sosa J, Gonzalez Lucero L, Barbaglia AL, Maldonado Ficco H, Citera G. Depression Is a Major Driver of Functional Capacity in Patients with Rheumatoid Arthritis Regardless of Disease Activity [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/depression-is-a-major-driver-of-functional-capacity-in-patients-with-rheumatoid-arthritis-regardless-of-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-is-a-major-driver-of-functional-capacity-in-patients-with-rheumatoid-arthritis-regardless-of-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology